9月5日，港股医药板块迎来强势反弹，其中北海康成-B（01228.HK）表现尤为亮眼。盘中数据显示，该股大涨10.86%，引发市场广泛关注。
除北海康成-B外，多只医药股同步上涨。欧康维视生物-B（01477.HK）涨幅最大，达11.99%；宜明昂科-B（01541.HK）紧随其后，上涨10.73%；康诺亚-B（02162.HK）也录得8.61%的涨幅。这一轮集体上涨凸显了投资者对医药板块的信心正在恢复。
分析人士认为，港股医药板块的集体反弹可能与近期市场风险偏好提升有关。同时，随着全球经济复苏和医疗需求持续增长，投资者对医药股的长期发展前景保持乐观态度。然而，投资者仍需密切关注个股基本面和行业政策变化，谨慎评估投资风险。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.